Daicel Corporation (DACHF) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Daicel Corporation stock $11.94, price $9.23, upside +29.3%, quality 49 out of 100. Rating: undervalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $4.83 – $9.80 · fair‑value band $6.79 – $16.74 · the $9.23 price screens below the $11.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Daicel in your weekly email
Every Wednesday you see whether Daicel is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally.
Show moreShow less
The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services.
It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents; and lenses used in VR, smartphones and various sensors.
In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems.
Further, it provides Engineering plastics comprising polyacetal, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers.
The company's products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011.
Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.
Stock analysis
Daicel Corporation (DACHF) currently trades at $9.23, while our model-based Fair Value estimate is $11.94, implying the stock looks roughly 23% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $8.27 per share, and 3 of the 19 models we run sit above the $9.23 price.
Bear case: the Growth Earnings group reads lowest at $3.48, and 16 of the 19 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $6.79 (bear) to $16.74 (bull), the price of $9.23 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daicel Corporation reported revenue of ¥583B in FY2026 versus ¥468B in FY2022, a compound +5.7%/yr. Reported net income was ¥10.2B in FY2026, compounding −24.3%/yr from FY2022.
Key figures
Market cap $2.7B Mid · P/E ratio 36.9 · EPS (TTM) $0.2500 · Dividend yield 5.4% · Net margin 1.6% · Return on equity 2.9% · Return on assets (EBIT) 6.7% (5-year average) · Operating margin 9.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 2% below its 52-week high and 15% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 29%, DACHF screens cheaper than that median.
Fair Value models
Bear$6.79Fair Value $11.94Bull$16.74
Price $9.23 · Upside +29.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.1527 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income$6.52$6.43$6.5476
EPV$2.52$3.69$4.7373
5Y EBITDA Exit$5.21$12.12$19.8772
All 21 models by family
DCF Models
5Y Revenue Exit$1.98$6.41$11.9568
5Y EBITDA Exit$5.21$12.12$19.8772
5Y P/E Exitn/an/a$0.890068
10Y Revenue Exitn/a$3.56$8.2164
10Y EBITDA Exit$2.21$7.47$14.0563
10Y P/E Exitn/an/a$0.060061
Earnings-Based
Graham-Dodd$1.72$3.82$4.8866
PEG = 1.0$0.6100$0.8800$1.1457
EPV$2.52$3.69$4.7373
Dividend Discount
Gordon GGM$3.77$6.18$9.0267
DDM Multi-Stage$3.77$5.56$7.6566
Multiples
P/E Multiple$3.23$4.30$5.3863
P/S Multiple$3.23$4.30$5.3858
P/B Multiple$19.27$25.69$32.1255
EV/EBIT$5.13$8.79$12.4564
EV/EBITDA$10.07$15.38$20.6966
EV/Revenue$3.66$7.74$11.8251
Asset-Based
NCAV (Graham)$4.28$5.74$8.5654
Economic Profit
Residual Income$6.52$6.43$6.5476
ROIC Compounder$2.52$3.69$4.7371
Growth Earnings
Growth-Adj P/E$2.44$3.48$4.5367
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2021 (pandemic). Over 10 years: +2.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.6%
Dividend (yield on the price)5.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.3% vs −10.0%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 7%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +52.5% a year for the price and +1.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 728 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside+29.3% · Top 25%
Profitability
Return on equity (12 months)2.9% · Below median
Return on assets1.2% · Below median
Net margin (12 months)1.6% · Bottom 25%
Operating margin (12 months)9.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)15.8% · Above median
Dividend yield (12 months)5.4% · Top 25%
Balance sheet
Debt / equity0.67× · Highest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daicel Corporation Fair Value". https://www.fairvalue-calculator.com/stock/DACHF
Frequently asked questions
Is Daicel Corporation (DACHF) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $11.94 versus the last price from Oct 30, 2026 of $9.23, about +29% upside (undervalued).
What is the fair value of DACHF?
Our model-based fair value for Daicel Corporation is $11.94 (as of Nov 8, 2026), built from audited fundamentals. Last price (from Oct 30, 2026): $9.23.
What is the quality score of DACHF?
Daicel Corporation has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daicel Corporation (DACHF)?
Our model-based price target is the fair value of $11.94 (as of Nov 8, 2026) from 21 valuation models. Cautious scenario $6.79, optimistic scenario $16.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Daicel Corporation stock forecast for 2026?
Our models put fair value at $11.94, about +29% upside versus the last price from Oct 30, 2026 of $9.23 (undervalued). Cautious scenario $6.79, optimistic scenario $16.74. The calculation is refreshed regularly with new filings.
What is the revenue of Daicel Corporation (DACHF)?
Daicel Corporation reported trailing-twelve-month revenue of about ¥615B (latest available figure, as of Nov 8, 2026).
Does Daicel Corporation pay a dividend?
Daicel Corporation currently shows a dividend yield of 5.41% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Daicel Corporation (DACHF) and when is the ex-dividend date?
Daicel Corporation has a dividend yield of 5.4%. The next ex-dividend date is Mar 30, 2027. A dividend has been paid every year since at least 2010. The payout ratio is 197% of earnings. Free cash flow covers the dividend 0.13 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into Daicel Corporation (DACHF)?
For today's price to be fair in a discounted-cash-flow model, Daicel Corporation would have to grow free cash flow by +55.7 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of DACHF use?
Our models discount Daicel Corporation at 8.6 %: a base by market capitalisation (mid), damped by beta 0.53, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daicel Corporation that is +55.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Daicel Corporation (DACHF) delivered so far?
Over the past 5 years revenue at Daicel Corporation grew +8.2 % a year. The price currently implies free-cash-flow growth of +55.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daicel Corporation (DACHF) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Daicel Corporation (+55.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daicel Corporation (DACHF)?
The free-cash-flow yield on the price is 0.68 %: that much free cash flow Daicel Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daicel Corporation (DACHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daicel Corporation it is $11.94 per share (as of Nov 8, 2026), against a price of $9.23. It is the blended result of 21 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daicel Corporation stock overvalued or undervalued in 2026?
As of Nov 8, 2026, DACHF trades below its calculated fair value: price $9.23, fair value $11.94, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DACHF?
No. The price is what the market pays today ($9.23); the fair value is what the company's own numbers justify ($11.94). For Daicel Corporation the two are $2.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Daicel Corporation worth?
The market values Daicel Corporation at about $2.7B (market capitalisation, as of Nov 8, 2026). Per share that is $9.23; our models calculate a fair value of $11.94 per share.
What do the bullish and bearish scenarios say about DACHF?
Our models span a range for Daicel Corporation: cautious scenario $6.79, base $11.94, optimistic $16.74 per share (as of Nov 8, 2026, price $9.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DACHF?
Daicel Corporation trades at a price-to-earnings ratio of 36.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $11.94 is built from several models across several years. Other multiples: P/B 1.2, P/S 0.7, EV/EBITDA 6.3.
How solid is the balance sheet of Daicel Corporation (DACHF)?
Balance-sheet figures for Daicel Corporation (as of Nov 8, 2026): return on equity 2.9%, debt of 0.67 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is DACHF from its 52-week high?
Daicel Corporation trades at $9.23, about 2% below its 52-week high of $9.38 and 15% above the low of $8.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $11.94 is for.
Which stocks are comparable to Daicel Corporation?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daicel Corporation stock attractive at the current price?
The data as of Nov 8, 2026: price $9.23, calculated fair value $11.94 (+29%), Quality Score 49/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DACHF calculated?
We run Daicel Corporation through 21 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $11.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daicel Corporation currently trades 23% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daicel Corporation (DACHF)?
The latest price we hold is from Oct 30, 2026 and stands at $9.23. Our model-based fair value is $11.94, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daicel Corporation right now?
A fairly wide model range ($6.79 to $16.74) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Daicel Corporation (DACHF) come from?
Earnings per share at Daicel Corporation grew +3.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +5.9 %, EBIT margin −3.7 %, tax rate −0.1 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Daicel Corporation
How large is the market capitalisation of Daicel Corporation (DACHF)?
The market capitalisation of Daicel Corporation is $2.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Daicel Corporation (DACHF)?
Earnings per share at Daicel Corporation are $0.2500 (price ÷ EPS = P/E 36.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daicel Corporation (DACHF)?
The dividend yield of Daicel Corporation is 5.4% (payout 200%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daicel Corporation (DACHF)?
The net margin of Daicel Corporation is 1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daicel Corporation (DACHF)?
The return on equity (ROE) of Daicel Corporation is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daicel Corporation (DACHF)?
On an EBIT basis the return on assets of Daicel Corporation is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daicel Corporation (DACHF)?
The operating margin of Daicel Corporation is 9.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daicel Corporation (DACHF)?
Revenue at Daicel Corporation is growing +15.8% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daicel Corporation (DACHF)?
Earnings per share at Daicel Corporation are growing +2.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Daicel Corporation (DACHF) carry?
The net debt of Daicel Corporation is ¥237B (fiscal year 2026, ≈ 93.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daicel Corporation in the live analysis
One click puts Daicel Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026